Press release content from PR Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from PR Newswire
Press release content from PR Newswire. The AP news staff was not involved in its creation.

AnPac Bio-Medical Science Announces Cooperation with Dragon Gate Investment Partners

March 3, 2020 GMT

SAN JOSE, Calif., March 3, 2020 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio” or the “Company”) (NASDAQ: ANPC), a biotechnology company specialized in early cancer screening and detection, today announced that it has engaged Dragon Gate Investment Partners as its financial advisor.

“As a fast-growing biotech company, we strive to build trust with investors,” said Dr. Chris Chang Yu, Chairman and CEO of AnPac Bio. “AnPac Bio’s CDA technology has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. Our mission is to catch cancer early and save lives. By cooperating with Dragon Gate Investment Partners, we believe that it is a good start for us to better inform the market about our strengths, promising patents and technology, and our growth potential.”

“AnPac Bio-Medical Science has 121 patents granted and 89 patents pending globally as of September 30, 2019. AnPac Bio has also engaged Dr. Michael Levitt, 2013 Nobel Laureate in Chemistry, as Chief Consultant of AnPac Bio’s innovation and Technical Committee. We are honored to have the opportunity to work with AnPac Bio’s outstanding management team,” said Ms. Lijie Zhu, Managing Director of Dragon Gate Investment Partners. “We anticipate helping the company to bridge the communication gap between the biotech world and the investor community.”

About Dragon Gate Investment Partners

Headquartered in New York City’s Midtown Manhattan, Dragon Gate Investment Partners is a unique investment firm with a special focus on globalizing and localizing sustainable and promising companies in the U.S. and China. The team has well-earned reputation of excellence in providing sensible and cost-effective cross-border business solutions for a wide breadth of clientele, including public companies, financial institutions, and high-net-worth individuals.

About AnPac Bio-Medical Science Co., Ltd.

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 121 issued patents as of September 30, 2019. With two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. In a recent market research report by Frost & Sullivan, AnPac Bio ranked second worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 35,000 clinical samples as at June 30, 2019. These clinical samples demonstrated that AnPac Bio’s CDA technology and platform could detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information, please visit: https://www.anpacbio.com

Rider A:

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “target,” “aim,” “predict,” “outlook,” “seek,” “goal” “objective,” “assume,” “contemplate,” “continue,” “positioned,” “forecast,” “likely,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; and our relationship with our major business partners and customers. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

IR Contact:
Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: ANPC@dgipl.com

View original content: http://www.prnewswire.com/news-releases/anpac-bio-medical-science-announces-cooperation-with-dragon-gate-investment-partners-301015407.html

SOURCE AnPac Bio-Medical Science Co., Ltd.